On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Systems biology and "omics" (1)
- Cardiovascular continuum
- Proteomics (1)
- Proteomics (2)
- Publications on proteomics
- Rationale for proteomic studies
- Samples
- Platforms
- LC-MS/MS platform
- Technical challenges
- Post translational modifications
- Unravelling pathophysiology (1)
- Epicardial fat
- Unravelling pathophysiology (2)
- Western blot and IHC
- NBT assay of ROS
- Biomarker of disease
- Urinary proteomics (CE/MS platform)
- Why urine?
- CE/MS platform
- Methods (1)
- Methods (2)
- Patients
- 239 biomarker panel
- Identification of proteins
- Single marker
- Two markers
- Three markers
- Better discrimination with more markers
- Effect of drug therapy
- Pre-eclampsia (1)
- Pre-eclampsia (2)
- Normal pregnancy
- Maternal risk factors
- Study design
- Clinical characteristics
- Pregnancy specific proteomic biomarkers
- Pre-eclampsia specific biomarkers (1)
- Pre-eclampsia specific biomarkers (2)
- Change in classification factor
- Sequencing
- Plasma proteome
- Pre-eclampsia and cardiovascular risk
- Serum proteomics (1)
- Serum proteomics (2)
- Urinary proteomics (SELDI) (1)
- Urinary proteomics (SELDI) (2)
- Organ damage
- Stroke (1)
- Stroke (2)
- Heart failure
- Biomarker of risk
- Chronic kidney disease pattern
- Diabetic nephropathy (1)
- Diabetic nephropathy (2)
- Study flow chart
- Integrating "omics" data
- Systems biology and "omics" (2)
- Summary and conclusions
- Acknowledgements
Topics Covered
- Systems biology
- Definition of proteomics
- Proteomics: rationale and practical aspects
- Proteomics in cardiovascular pathophysiology
- Proteomics to detect biomarkers of cardiovascular disease
- Urinary proteomics using capillary electrophoresis / mass spectrometry
- Proteomics of coronary artery disease
- Proteomics of pre-eclampsia
- Proteomics of other cardiovascular diseases: stroke, heart failure, diabetic nephropathy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Delles, C. (2013, November 5). Proteomics in cardiovascular disease: clinical considerations [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 14, 2025, from https://doi.org/10.69645/TGUN8661.Export Citation (RIS)
Publication History
- Published on November 5, 2013
Financial Disclosures
- Dr. Christian Delles has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Proteomics in cardiovascular disease: clinical considerations
Published on November 5, 2013
34 min